$TAK

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

Takeda's Phase 3 G-HOPE-001 trial of TAK-921 met primary endpoints, showing significant overall and progression-free survival benefits in advanced gastric cancer. The results advance the drug toward regulatory filings in Asia.

Takeda's ENTYVIO trial (VERDICT) showed treating ulcerative colitis to disease clearance (symptomatic, endoscopic, histologic remission) reduced complication risk by ~70% vs. symptomatic remission alone. Over 50% of patients achieved targets by Week 48. ENTYVIO's safety profile remained consistent with prior data. The study supports deeper remission goals for long-term disease control.

Takeda Pharmaceutical's average stock price target increased from $20.58 to $20.74, with a range of $16.96 to $23.36, according to 14 analysts. This implies a 9% upside based on the Oct. 14 closing price. The consensus rating remains 'Buy' among 17 analysts.

Takeda Pharmaceutical has launched ORZEYFUL, a new treatment for type 1 narcolepsy, in Japan and China. The drug, discovered by Takeda scientists, is designed to restore orexin signaling and address the biological cause of the disease. Clinical studies showed significant improvements in symptoms and quality of life compared to placebo. ORZEYFUL is an oral orexin receptor 2 (OX2R) agonist, and Takeda plans to launch it in the U.S. next month.

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) announced its 2nd quarter fiscal year 2026 earnings call on October 29, 2026. The call will feature presentations and Q&A in English and Japanese, with key executives participating. Presentation materials will be available on Takeda's website before the call, and a replay will be provided afterward.

Takeda Pharmaceutical (TAK) presented Phase 2/3 study results for TAK-881, showing a 42.6% reduction in infusion time for Primary Immunodeficiency Disease (PID) patients. The therapy met primary endpoints, demonstrating comparable efficacy and safety to HYQVIA. Takeda plans regulatory submissions in 2026. TAK stock is currently trading at $18.66, up 0.76%.

Takeda's zasocitinib showed superior efficacy over Bristol Myers Squibb's deucravacitinib in treating moderate to severe plaque psoriasis, with 36.5% of participants achieving complete clearance vs. 13.9%, according to a phase 3 study presented at the European Academy of Dermatology and Venerology Congress. Zasocitinib also demonstrated faster and more complete effects, with no new safety signals observed.

Novartis, Thermo Fisher, Takeda, Rockwell Automation, and others launched the Digital CMC Consortium to modernize drug development. The group aims to replace manual processes with digital standards, AI, and interoperable infrastructure. Novartis and Rockwell Automation highlighted cost-sharing and efficiency benefits. The consortium's initial focus is improving technology transfer in pharmaceutical manufacturing.

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.